Astellas and Seagen Announce Initial Results of PADCEV®

/PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc. (Nasdaq:SGEN) today announced the initial...

Related Keywords

California , United States , Tokyo , Japan , Washington , Canada , Switzerland , Seattle , Kenji Yasukawa , Daniel Petrylak , Ahsan Arozullah , Enfortumab Vedotin , Cancer Signaling Networks , Urology Care Foundation , Astellas Pharma Us Inc , Yale Cancer Center , Seagen Inc , Nasdaq , Stage Development , Exchange Commission , Astellas Pharma Inc , European Union , Most Common Adverse Reactions Including Laboratory Abnormalities , Prnewswire Astellas Pharma Inc , Cancers Symposium , Important Safety Information , Vice President , Medical Sciences Oncology , Yale School , Medicine Professor , Medical Oncology , Marjorie Green , Senior Vice President , Late Stage Development , Important Safety , Toxic Epidermal Necrolysis , Common Adverse Reactions , Including Laboratory Abnormalities , Drug Interactions , Dualp Gp , Prescribing Information , Focus Area Approach , Seagen Collaboration , Annual Report , Molecular Characterization , Muscle Invasive Bladder , Muscle Invasive Bladder Cancer , Accessed February , Astellas Pharma , Vedotin Antibody Drug Conjugate Targeting , Highly Potent Therapeutic Agent , Multiple Preclinical Cancer , Cancer Res ,